EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Strategic and Chemical Advances in Antibody–Drug Conjugates

Ibrahim A Alradwan iD, Meshal K Alnefaie, Nojoud Al Fayez, Alhassan H Aodah, Majed A Majrashi, Meshael Alturki, Mohannad M Fallatah, Fahad A Almughem iD, Essam A Tawfik, Abdullah A Alshehri iD

Pharmaceutics · 05.09.2025 · 17 (9) · 1164

DOI: 10.3390/pharmaceutics17091164 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Pharmaceutics, online erschienen am 05.09.2025. Verfasst von Ibrahim A Alradwan und 9 weiteren Autor:innen. Beteiligte Einrichtung: Advanced Diagnostics and Therapeutics Institute, Health Sector, King Abdulaziz City for Science and Technology (KACST), Riyadh 11442, Saudi Arabia. Die Arbeit wurde bisher 43-mal zitiert (Crossref) und nennt 177 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Antibody–drug conjugates (ADCs) are a rapidly advancing class of targeted cancer therapeutics that couple the antigen specificity of monoclonal antibodies (mAbs) with the potent cytotoxicity of small-molecule drugs. In their core design, a tumor-targeting antibody is covalently linked to a cytotoxic payload via a chemical linker, enabling the selective delivery of highly potent agents to malignant cells while sparing normal tissues, thereby improving the therapeutic index. Humanized and fully human immunoglobulin G1(IgG1) antibodies are the most common ADC backbones due to their stability in systemic circulation, robust Fcγ receptor engagement for immune effector functions, and reduced immunogenicity. Antibody selection requires balancing tumor specificity, internalization rate, and binding affinity to avoid barriers to tissue penetration, such as the binding-site barrier effect, while emerging designs exploit tumor-specific antigen variants or unique post-translational modifications to further enhance selectivity. Advances in antibody engineering, linker chemistry, and payload innovation have reinforced the clinical success of ADCs, with more than a dozen agents FDA approved for hematologic malignancies and solid tumors and over 200 in active clinical trials. This review critically examines established and emerging conjugation strategies, including lysine- and cysteine-based chemistries, enzymatic tagging, glycan remodeling, non-canonical amino acid incorporation, and affinity peptide-mediated methods, and discusses how conjugation site, drug-to-antibody ratio (DAR) control, and linker stability influence pharmacokinetics, efficacy, and safety. Innovations in site-specific conjugation have improved ADC homogeneity, stability, and clinical predictability, though challenges in large-scale manufacturing and regulatory harmonization remain. Furthermore, novel ADC architectures such as bispecific ADCs, conditionally active (probody) ADCs, immune-stimulating ADCs, protein-degrader ADCs, and dual-payload designs are being developed to address tumor heterogeneity, drug resistance, and off-target toxicity. By integrating mechanistic insights, preclinical and clinical data, and recent technological advances, this work highlights current progress and future directions for next-generation ADCs aimed at achieving superior efficacy, safety, and patient outcomes, especially in treating refractory cancers.

Schlagwörter

Stichwörter der Autor:innen

antibody–drug conjugatescysteine conjugationdrug-to-antibody ratioenzymatic taggingglycan remodelinglinker chemistrylysine conjugationnon-canonical amino acidssite-specific conjugationtargeted cancer therapy

Autor:innen und Institutionen

  • Advanced Diagnostics and Therapeutics Institute, Health Sector, King Abdulaziz City for Science and Technology (KACST), Riyadh 11442, Saudi Arabia.
  • Bioengineering Institute, Health Sector, King Abdulaziz City for Science and Technology (KACST), Riyadh 11442, Saudi Arabia.
  • Wellness and Preventative Medicine Institute, Health Sector, King Abdulaziz City for Science and Technology (KACST), Riyadh 11442, Saudi Arabia.

ORCID-Profile: Ibrahim A Alradwan, Fahad A Almughem, Abdullah A Alshehri

Zitieren

APA

Alradwan, I. A., Alnefaie, M. K., Al Fayez, N., Aodah, A. H., Majrashi, M. A., Alturki, M., Fallatah, M. M., Almughem, F. A., Tawfik, E. A., & Alshehri, A. A. (2025). Strategic and Chemical Advances in Antibody–Drug Conjugates. Pharmaceutics, 17(9), 1164. https://doi.org/10.3390/pharmaceutics17091164

Vancouver

Alradwan IA, Alnefaie MK, Al Fayez N, Aodah AH, Majrashi MA, Alturki M, et al. Strategic and Chemical Advances in Antibody–Drug Conjugates. Pharmaceutics. 2025;17(9):1164. doi:10.3390/pharmaceutics17091164

BibTeX
@article{Alradwan2025,
  author = {Alradwan, Ibrahim A and Alnefaie, Meshal K and Al Fayez, Nojoud and Aodah, Alhassan H and Majrashi, Majed A and Alturki, Meshael and Fallatah, Mohannad M and Almughem, Fahad A and Tawfik, Essam A and Alshehri, Abdullah A},
  title = {Strategic and Chemical Advances in Antibody–Drug Conjugates},
  journal = {Pharmaceutics},
  year = {2025},
  volume = {17},
  number = {9},
  pages = {1164},
  doi = {10.3390/pharmaceutics17091164}
}
Kostenlos starten →